Dermatologic Agents (administration & dosage) < Dermatologic Agents (adverse effects) < Dermatologic Agents (antagonists & inhibitors)

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f KwdFr.f

List of bibliographic references indexed by Dermatologic Agents (adverse effects)

Number of relevant bibliographic references: 17.

Ident.	Authors (with country if any)	Title
000196 (2019)	S. D'Adamio [Italie] ; D. Silvaggio [Italie] ; P. Lombardo [Italie] ; L. Bianchi [Italie] ; M. Talamonti [Italie] ; M. Galluzzo [Italie]	The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
000710 (2018)	E. Peleva [Royaume-Uni] ; L S Exton [Royaume-Uni] ; K. Kelley [Royaume-Uni] ; C E Kleyn [Royaume-Uni] ; K J Mason [Royaume-Uni] ; C H Smith [Royaume-Uni]	Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
000932 (2018)	K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne]	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
000B06 (2017)	A B Gottlieb [États-Unis] ; J-P Lacour [France] ; N. Korman [États-Unis] ; S. Wilhelm [Allemagne] ; Y. Dutronc [France] ; A. Schacht [Allemagne] ; J. Erickson [États-Unis] ; L. Zhang [États-Unis] ; L. Mallbris [États-Unis] ; S. Gerdes [Allemagne]	Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
001302 (2016)	R B Warren [Royaume-Uni] ; S C Weatherhead [Royaume-Uni] ; C H Smith [Royaume-Uni] ; L S Exton [Royaume-Uni] ; M F Mohd Mustapa [Royaume-Uni] ; B. Kirby [Irlande (pays)] ; P D Yesudian [Royaume-Uni]	British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.
001370 (2015)	Patricia Shu Kurizky [Brésil] ; Clarissa De Castro Ferreira [Brésil] ; Lucas Souza Carmo Nogueira [Brésil] ; Licia Maria Henrique Da Mota [Brésil]	Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.
001877 (2014)	Nawaf Al-Mutairi [Éthiopie] ; Tarek Nour	The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
001C71 (2013)	Emily Yiping Gan [Singapour] ; Wei-Sheng Chong ; Hong Liang Tey	Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
002115 (2012)	W. Sterry [Allemagne] ; P. Van De Kerkhof	Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
002427 (2011)	M. Talamonti [Italie] ; M. Teoli ; E. Botti ; G. Spallone ; S. Chimenti ; A. Costanzo	Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
002909 (2009)	Lluís Puig Sanz [Espagne] ; E. Sáez ; M J Lozano ; X. Bordas ; J M Carrascosa ; F. Gallardo ; J. Luelmo ; M. Sánchez-Rega A ; M. Alsina ; V. García-Patos	[Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].
002927 (2009)	Alan Menter [États-Unis]	The status of biologic therapies in the treatment of moderate to severe psoriasis.
002B68 (2008)	Richard B. Warren [Royaume-Uni] ; Christopher E M. Griffiths	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine.
002B82 (2008)	L. Puig [Espagne]	[Which patient is a candidate for treatment with efalizumab and why?].
002B84 (2008)	J L Sánchez Carazo [Espagne] ; L. Martínez Casimiro ; V. Alegre De Miguel	[Long-term control of psoriasis is necessary].
002B85 (2008)	E. Calabuig [Espagne] ; M. Salavert	[Infectious risk].
003276 (2006)	Daniel J. Pearce [États-Unis] ; Kristen B. Higgins ; Katherine H. Stealey ; Rajesh Balkrishnan ; Martin M. Crane ; Fabian Camacho ; Alan B. Fleischer ; Steven R. Feldman	Adverse events from systemic therapies for psoriasis are common in clinical practice.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Dermatologic Agents (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Dermatologic Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dermatologic Agents (adverse effects)
}}

---

This area was generated with Dilib version V0.6.38. Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020